Actualités
Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
Lead program ABCL635 Phase 2 enrollment complete with data expected in August.
(Bloomberg) -- Biotech company AbCellera Biologics Inc. jumped as much as 41%, giving it a market value of almost $3 billion, after it said a potential remedy for hot flashes was effective in a mid-stage trial.Most Read from BloombergChina Unleashes $28 Trillion Capital Markets to Challenge US in AIIran Shakes Up Security Team After Saying Oman Deal ‘Very Close’Stocks Churn as Oil Advance Boosts Treasury Yields: Markets WrapTrump Amps Up Pressure on Billionaire Sargeant to Exit VenezuelaBehind B
AbCellera Biologics Inc (ABCL) advances ABCL-635 with early phase 2 completion and secures over $110 million in new T-cell engager deals, despite a wider net loss and revenue decline.
AbCellera Biologics (NASDAQ:ABCL) said it expects to report top-line data “very soon” from its Phase I study of ABCL635, an antibody being evaluated for moderate-to-severe vasomotor symptoms, or hot flashes, associated with menopause. President and Chief Executive Officer Dr. Carl Hansen said enrol
AbCellera Biologics Inc (ABCL) progresses its lead program into Phase II, despite reporting a net loss and increased R&D expenses.
AbCellera Biologics (NASDAQ:ABCL) said its first quarter of 2026 was marked by progress in its internal drug pipeline, including interim Phase 1 data for its lead program, ABCL635, and continued preparation for multiple clinical catalysts expected over the next two years. President and CEO Dr. Carl
Tryn Stimart: Thank you for joining us for AbCellera Biologics Inc.'s First Quarter 2026 Earnings Call. Doctor Carl L. Hansen, AbCellera Biologics Inc.'s President and CEO, Doctor Sarah Noonberg, AbCellera Biologics Inc.'s Chief Medical Officer, and Andrew Booth, AbCellera Biologics Inc.'s Chief Financial Officer, are speaking on today's call.